Search Results - "Yubero, A."

SEOM clinical guidelines for cervical cancer (2019) by de Juan, A., Redondo, A., Rubio, M. J., García, Y., Cueva, J., Gaba, L., Yubero, A., Alarcón, J., Maximiano, C., Oaknin, A.

“…Cervical cancer (CC) is the fourth most common cancer in women worldwide, strongly linked to high-risk human papilloma virus infection. In high-income…”
Get full text

XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer by FELIU, J, SALUD, A, DE MON, M. A, CASADO, E, GONZALEZ-BARON, M, ESCUDERO, P, LOPEZ-GOMEZ, L, BOLANOS, M, GALAN, A, VICENT, J.-M, YUBERO, A, LOSA, F, DE CASTRO, J

“…The purpose of this phase II trial was to determine the efficacy and safety of the XELOX (capecitabine/oxaliplatin) regimen as first-line therapy in the…”
Get full text

Successful Desensitization to Irinotecan After Severe Hypersensitivity Reaction by Cubero, J L, Escudero, P, Yubero, A, Millán, P, Sagredo, M A, Colás, C

Get full text

Assessment of functional status, symptoms and comorbidity in elderly patients with advanced non-small-cell lung cancer (NSCLC) treated with gemcitabine and vinorelbine by Maestu, I, Muñoz, J, Gómez-Aldaraví, L, Esquerdo, G, Yubero, A, Torregrosa, M D, Romero, R

“…The incidence and prevalence of comorbid conditions in lung cancer patients increase with age. The aim of the study was to determine response and tolerability…”
Get full text

8520 Preliminary results of a pilot study with a modified induction docetaxel/cisplatin/5-FU (TPF) followed by concomitant chemoradiotherapy (CT/RT) in locally advanced head and neck cancer (LAHNC) by Serrano, S, Martinez-Trufero, J, Miguelsanz, S, Yubero, A, Lastra, R, Polo, E, Lambea, J, Seguí, M.A, Pujol, E, Isla, D

Get full text

Reversible peripheral neuropathy induced by a single administration of high-dose paclitaxel by INIGUEZ, C, LARRODE, P, MAYORDOMO, J. I, GONZALEZ, P, ADELANTADO, S, YUBERO, A, TRES, A, MORALES, F

“…Peripheral neuropathy (PN) is the main side effect with cycles of paclitaxel at standard doses (175 mg/m2 for 21 days). Administration of a single high-dose…”
Get full text

A phase II study of pembrolizumab in combination with doxorubicin in advanced, recurrent or metastatic endometrial cancer by Oaknin, A., Perez, M J Rubio, Madrid, L Fariñas, Redondo, A., Esteban, A Yubero, Martín, M Gil, Martín, A González, Romero, I., Garcia-Donas, J., Serrano, R., Martínez, A Gallego, Diez, M Ocariz, Lorenzo, M L Sanchez, De La Maza Lopez Olmedo, M D Fenor, Freixinos, V Rodriguez, Rodriguez, J M Piulats

Get full text

1062TiP - A phase II study of pembrolizumab in combination with doxorubicin in advanced, recurrent or metastatic endometrial cancer by Oaknin, A., Perez, M J Rubio, Madrid, L Fariñas, Redondo, A., Esteban, A Yubero, Martín, M Gil, Martín, A González, Romero, I., Garcia-Donas, J., Serrano, R., Martínez, A Gallego, Diez, M Ocariz, Lorenzo, M L Sanchez, De La Maza Lopez Olmedo, M D Fenor, Freixinos, V Rodriguez, Rodriguez, J M Piulats

“…New approaches are needed for patients with advanced endometrial cancer (EC) since there is no standard second-line therapy after failure to platinum-based…”
Get full text

1062TiPA phase II study of pembrolizumab in combination with doxorubicin in advanced, recurrent or metastatic endometrial cancer by Oaknin, A, Perez, M J Rubio, Madrid, L Fariñas, Redondo, A, Esteban, A Yubero, Martín, M Gil, Martín, A González, Romero, I, Garcia-Donas, J, Serrano, R, Martínez, A Gallego, Diez, M Ocariz, Lorenzo, M L Sanchez, De La Maza Lopez Olmedo, M D Fenor, Freixinos, V Rodriguez, Rodriguez, J M Piulats

“…Abstract Background New approaches are needed for patients with advanced endometrial cancer (EC) since there is no standard second-line therapy after failure…”
Get full text

55P Long-term responders (LTR) with niraparib maintenance in platinum-sensitive recurrent high-grade serous ovarian cancer (PSROC) focusing on subsequent therapies and post-progression outcomes (GEICO-88R study) by Banuelos, J.F. Cueva, Garcia, Y. Garcia, Esteban, A. Yubero, Martinez, A. Gallego, Bueno, A. Martinez, Quintana, J. Ferreiro, Gonzalez, S., Cassinello, J.G., Reche, P., Tabares, M.L. Soriano, Valero, M., Garcia, L. Gaba, Gordon Santiago, M.D.M., Raposo, C. Gomez, Polo, S. Hernando, Vazquez, R. Marquez, Pradera, J. Fuentes, Alarcon, J.D., Garcia, A. Taus, González-Martín, A.

Get full text

Capecitabine As First-Line Treatment for Patients Older Than 70 Years With Metastatic Colorectal Cancer: An Oncopaz Cooperative Group Study by FELIU, Jaime, ESCUDERO, Pilar, GOMEZ-REINA, Maria-José, GONZALEZ-BARON, Manuel, LLOSA, Ferran, BOLANOS, Matilde, VICENT, Jose-Manuel, YUBERO, Alfonso, SANZ-LACALLE, Jose-Javier, LOPEZ, Rafael, LOPEZ-GOMEZ, Luis, CASADO, Enrique

“…To determine the tolerability of capecitabine in elderly patients with advanced colorectal cancer (CRC). Fifty-one patients with advanced CRC who were >/= 70…”
Get full text

Docetaxel and carboplatin followed by sequential capecitabine as first line treatment in patients with locally advanced or metastatic breast cancer by Lorenzo, A, Modolell, A, Valero, P, Murillo, L, García-Bueno, JM, Yubero, A, Machengs, I

“…Abstract Abstract #2155 Background: Anthracyclines and docetaxel (D) are the most active agents in metastatic breast cancer (BC). New regimens are being…”
Get full text

A pilot study of modified neoadjuvant docetaxel/cisplatin/5-FU (TPF) to concomitant chemoradiotherapy (CT/RT) in locally advanced head and neck cancer (LAHNC): Preliminary results by Isla, D., Martínez-Trufero, J., Morales, S., Yubero, A., Lambea, J., Álvarez, I., Polo, E., Seguí, M. A., Pujol, E., Pastor, P.

“…Abstract only 6039 Background: Sequential treatment with induction CT followed by CT/RT is highly active and under study in ongoing randomized trials. We…”
Get full text

383P An exosome-based liquid biopsy assay for predicting therapeutic outcomes in patients with metastatic colorectal cancer treated with anti-EGFR therapy: Results from prospective, first-line, PULSE and POSIBA trials by Goel, A., Xu, C., Roy, S., Esposito, F.M., Helena, O., Alonso, V., Yubero Esteban, A., Carlos, F-M., Salud Salvia, M.A., Gallego Plazas, J., Rodriguez Monwbray, J.R., Marta, M.M-R., Fernandez, J., Manzano, H., Aparicio, J., Feliu, J., Maurel, J.

Get full text

605P First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort by Oliveres, H., Alonso-Orduna, V., Feliu, J., Fernandez Montes, A., Martin-Richard, M., Galvez Munoz, E., Ruiz-Casado, A., Yubero Esteban, A., Aparicio, J., Alcaide-Garcia, J., Gallego Plazas, J., Carmona-Bayonas, A., Fernandez Martos, C., Gallego, M.R., Manzano Alemany, H., Leno, R., Esposito, F.M., Sapena, V., Maurel, J.

Get full text

560MO Maintenance with 5FU/LV-Aflibercept after induction with FOLFIRI-Aflibercept vs FOLFIRI-Aflibercept until progression in older patients (pts) in 2nd line metastatic colorectal cancer (mCRC): The randomized AFEMA trial by García Alfonso, P., Elez Fernandez, M.E., Soto Alsar, J., Paez, D., Fernandez Montes, A., Grana Suarez, B., Salud, A., Yubero Esteban, A., Gomez España, M.A., Macias Declara, I., Quintero Aldana, G.A., Lopez Lopez, C., Fernandez Rodriguez, T., Gravalos Castro, M.C., González-Flores, E., Guix Arnau, M., García Paredes, B., Reina Zoilo, J.J., Sastre Varela, J., Aranda Aguilar, E.

Get full text

798P A phase II study of pembrolizumab (P) in combination with doxorubicin (D) in advanced endometrial cancer (AEC): TOPIC trial/VHIO10001 by Fariñas-Madrid, L., Rubio, M.J., Redondo, A., Villacampa Javierre, G., Yubero Esteban, A., Romero, I., Gil-Martin, M., Garcia-Donas, J., González-Martín, A., Gallego Martinez, A., Grau, F., Ruiz-Pace, F., Pardo Búrdalo, B., Sanchez Lorenzo, M.L., Piulats, J.M., Oaknin, A.

Get full text

Measurement of energy resolution with the NEXT-White silicon photomultipliers by Contreras, T., Palmeiro, B., Para, A., Martínez-Lema, G., Guenette, R., Adams, C., Álvarez, V., Aparicio, B., Aranburu, A. I., Arazi, L., Arnquist, I. J., Auria-Luna, F., Ayet, S., Azevedo, C. D. R., Bailey, K., Ballester, F., del Barrio-Torregrosa, M., Bayo, A., Benlloch-Rodríguez, J. M., Borges, F. I. G. M., Brodolin, A., Cárcel, S., Castillo, A., Cebrián, S., Church, E., Cid, L., Conde, C. A. N., Cossío, F. P., Dey, E., Díaz, G., Dickel, T., Echevarria, C., Elorza, M., Escada, J., Esteve, R., Felkai, R., Fernandes, L. M. P., Ferrario, P., Ferreira, A. L., Foss, F. W., Freixa, Z., García-Barrena, J., Grocott, J. W. R., Hauptman, J., Henriques, C. A. O., Hernando Morata, J. A., Herrero-Gómez, P., Herrero, V., Hervés Carrete, C., Ifergan, Y., Jones, B. J. P., Kellerer, F., Larizgoitia, L., Larumbe, A., Lebrun, P., Lopez, F., Madigan, R., Mano, R. D. P., Marques, A. P., Martín-Albo, J., Martínez-Vara, M., Miller, R. L., Mistry, K., Molina-Canteras, J., Monrabal, F., Monteiro, C. M. B., Mora, F. J., Novella, P., Nuñez, A., Oblak, E., Palacio, J., Parmaksiz, I., Pazos, A., Pelegrin, J., Pérez Maneiro, M., Redwine, A. B., Renner, J., Rivilla, I., Rogero, C., Rogers, L., Romo-Luque, C., Santos, F. P., dos Santos, J. M. F., Seemann, M., Shomroni, I., Silva, P. A. O. C., Simón, A., Soleti, S. R., Sorel, M., Soto-Oton, J., Teruel-Pardo, S., Toledo, J. F., Tonnelé, C., Torrent, J., Trettin, A., Usón, A., Valle, P. R. G., Veloso, J. F. C. A., Waiton, J., Yubero-Navarro, A.

“…A bstract The NEXT-White detector, a high-pressure gaseous xenon time projection chamber, demonstrated the excellence of this technology for future…”
Get full text

A multicenter pilot study of adjuvant docetaxel, epirubicin and cyclophosphamide (TEC) in patients (p) with stage II/III and node-positive breast cancer (BC) by Mayordomo, J. I., Lorenzo, A., Modolell, A., Alvarez, I., Bayo, J., Machengs-M Centelles-K Villadiego, I., Rubio, M. J., Heras, L., Yubero, A., Gonzálvez, M. L., Valero, J.

“…Abstract only 11029 Background: Based on wide experience with docetaxel, adriamicin and cyclophosphamide (TAC regimen) for adjuvant therapy of node-positive BC…”
Get full text

Frequency of familiar cancer in a cohort of newly-diagnosed patients with colorectal cancer by Lastra, R., Yubero, A., Ortega, M., Lambea, J., Elena, A., Millastre, E., Ruiz, M., Escudero, P., Saenz, A., Mayordomo, J. I., Tres, A.

“…Abstract only 13588 Background: Incidence on Hereditary Non Poliposis Colorectal Cancer (HNPCC) is 3–5% of all colorectal cancers (CRC). Primary identification…”
Get full text